DBV Technologies S.A. (DBVT)
Market Cap | 131.17M |
Revenue (ttm) | 15.73M |
Net Income (ttm) | -72.73M |
Shares Out | 192.42M |
EPS (ttm) | -0.40 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 39,297 |
Open | 0.702 |
Previous Close | 0.690 |
Day's Range | 0.660 - 0.710 |
52-Week Range | 0.650 - 2.370 |
Beta | 0.76 |
Analysts | Strong Buy |
Price Target | 7.00 (+944.78%) |
Earnings Date | May 2, 2024 |
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respirato... [Read more]
Financial Performance
In 2023, DBVT's revenue was 15.73 million, an increase of 224.69% compared to the previous year's 4.84 million. Losses were -72.73 million, -24.46% less than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DBVT stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 944.78% from the latest price.
News
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq ...
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 thr...
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Ma...
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceuti...
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Montrouge, France, January 16, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq St...
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut show...
DBV Technologies to Present New Data at ACAAI 2023
Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label...
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results
Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV ha...
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT...
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: D...
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, September 5, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stag...
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'...
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market...
DBV Technologies to Participate in Upcoming EAACI Congress 2023
Montrouge, France, June 8, 2023 DBV Technologies to Participate i n Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage bio...
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal o...
DBV Technologies Reports First Quarter 2023 Financial Results
Montrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – I...
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company's...
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euron...
Ordinary and Extraordinary General Meeting of April 12, 2023
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Me...
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
Montrouge, France, March 7, 2023
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
Montrouge, France, March 2, 2023
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
Montrouge, France, March 2, 2023
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
Montrouge, France, February 27, 2023